newsfilter
← Latest News
GlobeNewswire·

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug Application (NDA)